Evidence map›Paper›PMID 21383914›Full record

ArticleBiologics : targets & therapy2011

An update on belimumab for the treatment of lupus.

Aikaterini Thanou-Stavraki, Amr H Sawalha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biologics : targets & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. [Belimumab. A new targeted therapeutic option for lupus erythematosus].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2012
    Article
  4. Belimumab: First targeted biological treatment for systemic lupus erythematosus.Journal of pharmacology & pharmacotherapeutics · 2011
    Article
  5. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2011
    Review
  6. Biomarkers in chronic graft-versus-host disease.Expert review of hematology · 2011
    Review
  7. HDAC inhibition in lupus models.Molecular medicine (Cambridge, Mass.)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Aikaterini Thanou-StavrakiDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;
Amr H Sawalha
University of Oklahoma Health Sciences Center · US

Funding

SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
NIAMS NIH HHS P30 AR053483
6 · The paper itself

Abstract

B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence of efficacy in several preclinical and clinical studies in SLE. Two recent large randomized controlled trials yielded a significant positive effect of the drug compared to placebo in patients with active disease. In this review, we discuss basic aspects of B-cell and BLyS biology in SLE and summarize the evidence supporting a role of belimumab in SLE, from animal studies to phase III clinical trials.

Indexed as

belimumabB lymphocyte stimulatorlupus erythematosus

Identifiers

PMID21383914
PMCPMC3044792
OpenAlexW2090304268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.